Sanofi is conducting a single-arm, open-label clinical trial to evaluate the safety and pharmacokinetics of teplizumab in pediatric patients under 8 years of age with Stage 2 Type 1 Diabetes. The study aims to enroll approximately 20 participants and will assess treatment-emergent adverse events, pharmacokinetics, and immunogenicity over a period of up to 26 months.